Cork, Ireland (ots/PRNewswire) - Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of ...
Cork, Ireland (ots/PRNewswire) - - Once-Daily TMC278 is the Third Anti-HIV Compound to be Developed in Tibotec Virology Portfolio Tibotec Pharmaceuticals is currently recruiting HIV-positive, treatment-naïve adults (or those who have never taken antiretroviral medication before) in Europe for two major ...
Cork, Ireland (ots/PRNewswire) - - For Medical Media Only - PREZISTA now Indicated for the Broad Range of Treatment-Experienced Patients in the 27 EU Member States Tibotec Pharmaceuticals announced today that the European Commission adopted the decision to broaden the indication for PREZISTA(R) ...
Cork, Ireland, November 27 (ots/PRNewswire) - The Committee for Human Medicinal Products (CHMP) has issued a positive opinion recommending approval for once-daily dosing of 800 mg PREZISTA(R) (darunavir) with low-dose ritonavir as part of combination therapy in treatment-naïve adults (those who have never taken ...
Cork, Ireland, November 20 (ots/PRNewswire) - - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined Treatment With Standard of Care New clinical data demonstrate the safety and antiviral activity of TMC435, an investigational protease inhibitor (PI) ...
Cork, Ireland, November 20 (ots/PRNewswire) - - Telaprevir Data Presented at AASLD Tibotec BVBA today announced that it has begun enrolling patients in its phase III study of telaprevir (VX-950), an investigational protease inhibitor (PI), in patients with chronic genotype 1 hepatitis C virus (HCV) for ...
Cork, Ireland (ots/PRNewswire) - -INTELENCE is the First NNRTI to Show Antiviral Activity in Patients With NNRTI-Resistant Virus The European Medicines Agency (EMEA) has granted marketing authorisation for the anti-HIV medication INTELENCE(TM) (etravirine). INTELENCE is a next generation non-nucleoside ...
Mexico City, Mexico (ots/PRNewswire) - - Ninety-Six-Week Data on Tibotec Investigational NNRTI Presented at AIDS 2008 New phase IIb data from Tibotec Pharmaceuticals Ltd. show that TMC278, the company's once-daily, investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), provides long-term efficacy and tolerability in treatment-naïve adults ...
Cork, Ireland (ots/PRNewswire) - - INTELENCE is the first NNRTI to demonstrate antiviral activity in patients with NNRTI-resistant virus - Tibotec Pharmaceuticals, Ltd. announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMEA) has issued a positive ...
Cork, Ireland (ots/PRNewswire) - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults(i) taking Prezista(R) (darunavir)/ritonavir, with an optimised background regimen (OBR) of antiretroviral agents, reached a viral ...
Cork, Ireland (ots/PRNewswire) - - Data Published in The Lancet on TMC125, an Investigational NNRTI from Tibotec TMC125 (etravirine, ETR), Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated significant efficacy in patients with NNRTI resistance, ...
Cork, Ireland (ots/PRNewswire) - - Data Published in The Lancet on TMC125, an Investigational NNRTI from Tibotec TMC125 (etravirine, ETR), Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated significant efficacy in patients with NNRTI resistance, ...
Cork, Ireland (ots/PRNewswire) - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults(i) taking Prezista(R) (darunavir)/ritonavir, with an optimised background regimen (OBR) of antiretroviral agents, reached a viral ...
Glasgow, Scotland, November 15 (ots/PRNewswire) - - Also Found Compatible with Other Medicines Used by HIV/AIDS Patients A review of 17 drug-drug interaction studies involving the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 was presented today as a plenary oral paper at the Eighth International Congress on Drug Therapy in HIV Infection (HIV8) in Glasgow, Scotland. The data ...
Glasgow, Scotland, November 14 (ots/PRNewswire) - - Also Found Compatible with Other Medicines Used by HIV/AIDS Patients A review of 17 drug-drug interaction studies involving the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 was presented today as a plenary oral paper at the Eighth International Congress on Drug Therapy in HIV Infection (HIV8) in Glasgow, Scotland. The data ...
Glasgow, Scotland, November 14 (ots/PRNewswire) - - Data Presented at HIV 8 Conference - New studies on the use of PREZISTA(TM), an investigational anti-HIV medication, suggest that it can be co-administered with many common medications taken by people with HIV, including other antiretrovirals, proton pump inhibitors, H2 blockers and selective serotonin reuptake inhibitors. According to current HIV ...
Toronto (ots/PRNewswire) - - TMC125 a Next-Generation NNRTI Tibotec Pharmaceuticals Ltd. presented 48 week efficacy and safety data on TMC125, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 16th International AIDS conference (IAC), AIDS 2006, in Toronto, Canada this week. TMC125 is currently being investigated in phase 3 trials (DUET 1 and 2) in treatment-experienced adult ...